Luxvisions Innovation Technology resubmitted its Hong Kong Main Board IPO prospectus to HKEX eight months after its initial filing lapsed, with CITIC Securities and CICC as joint sponsors.
Quay lại
Luxvisions Innovation refiles HK IPO after 8-month prospectus lapse
Luxvisions Innovation Technology resubmitted its Hong Kong Main Board IPO prospectus to HKEX, eight months after its initial 28 November 2025 filing lapsed.
CITIC Securities and CICC are the joint sponsors for the listing application, according to the filing. The company's first prospectus submission expired without advancing to the listing hearing stage, forcing the refiling to restart the exchange's vetting process.
HKEX (00388.HK) shares traded down 0.244 percent, with short selling of $35.87 million representing 8.207 percent of turnover as of 12:25 on 4 August 2026, exchange data show.
The company has not yet disclosed its proposed offer price, indicative deal size, or target listing date. Cornerstone investor commitments, use-of-proceeds allocation, and valuation metrics against comparable Main Board peers also remain pending in the updated prospectus.
Under HKEX listing rules, a prospectus filing lapses if the application does not progress within six months of submission. The refiling resets the regulatory clock, giving Luxvisions a fresh window to complete the vetting process and secure a listing hearing date.
The resubmission comes as Hong Kong's IPO pipeline continues to draw technology and innovation-focused issuers seeking access to mainland and international capital. The Main Board remains the preferred venue for larger listings, with the exchange's listing committee typically reviewing applications over several months from prospectus submission to hearing.
The refiling resets the regulatory timeline for Luxvisions' Main Board application. Investors will watch for the HKEX listing committee's review schedule and any updated financial disclosures to assess the company's valuation against sector peers.
This article is for informational purposes only and does not constitute investment advice.
